Two new series of pyrazolyl-thiazolidinone/thiazole derivatives
16a–b
and
18a–j
were synthesised, merging the scaffolds of celecoxib and dasatinib. Compounds
16a
,
16b
and
18f
inhibit
COX-2
with S.I. 134.6, 26.08 and 42.13 respectively (celecoxib S.I. = 24.09). Compounds
16a,
16b,
18c,
18d
and
18f
inhibit
MCF-7
with IC
50
= 0.73–6.25 μM (dasatinib IC
50
= 7.99 μM) and (doxorubicin IC50 = 3.1 μM) and inhibit
A549
with IC50 = 1.64–14.3 μM (dasatinib IC
50
= 11.8 μM and doxorubicin IC
50
= 2.42 μM) with S.I.
(F180/MCF7)
of 33.15, 7.13, 18.72, 13.25 and 8.28 respectively higher than dasatinib (4.03) and doxorubicin (3.02) and S.I.
(F180/A549)
of 14.75, 12.96, 4.16, 7.07 and 18.88 respectively higher than that of dasatinib (S.I. = 2.72) and doxorubicin (S.I = 3.88). Derivatives
16a, 18c, 18d, 18f
inhibit EGFR and HER-2 IC50 for EGFR of 0.043, 0.226, 0.388, 0.19 μM respectively and for HER-2 of 0.032, 0.144, 0.195, 0.201 μM respectively.